1426216-93-4
Chemical Structure
Abimufloxacin
Synonym(s): OPS-2071
- CAS No.: 1426216-93-4
- Formula:C20H15FN4O3
- Molecular Weight:378.36
IUPAC Name: 7-(6-amino-5-cyanopyridin-3-yl)-1-cyclopropyl-6-fluoro-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
InChIKey: DTSKYQBTFHFYAZ-UHFFFAOYSA-N
SMILES: N#CC=1C=C(C=NC1N)C2=C(F)C=C3C(=O)C(=CN(C3=C2C)C4CC4)C(=O)O
Biological Activity: Abimufloxacin (OPS-2071) is a broad-spectrum quinolone antibacterial agent. Abimufloxacin inhibits the supercoiling activity of DNA gyrase, the decatenation activity of topoisomerase IV, the activation and proliferation of T cells, macrophage activity, as well as the production of TNF-α and IFN-γ. Abimufloxacin exhibits activity against enteropathogenic Gram-positive bacteria, Gram-negative bacteria, quinolone-resistant bacteria, and Crohn's disease-associated bacteria (including Clostridioides difficile and Campylobacter jejuni). Abimufloxacin alleviates colonic inflammation in a mouse model of T cell-mediated colitis. Abimufloxacin can be used in research related to diseases such as intestinal infections and Crohn's disease[1][2].
| Cat. No. | 상품명 | Purity | 제품 설명 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Abimufloxacin | Abimufloxacin (OPS-2071) is a broad-spectrum quinolone antibacterial agent. Abimufloxacin inhibits the supercoiling activity of DNA gyrase, the decatenation activity of topoisomerase IV, the activation and proliferation of T cells, macrophage activity, as well as the production of TNF-α and IFN-γ. Abimufloxacin exhibits activity against enteropathogenic Gram-positive bacteria, Gram-negative bacteria, quinolone-resistant bacteria, and Crohn's disease-associated bacteria (including Clostridioides difficile and Campylobacter jejuni). Abimufloxacin alleviates colonic inflammation in a mouse model of T cell-mediated colitis. Abimufloxacin can be used in research related to diseases such as intestinal infections and Crohn's disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Oka D, et al. In vitro antibacterial activity of OPS-2071 against Gram-positive and Gram-negative enteropathogenic bacteria. The Journal of antimicrobial chemotherapy. 2022 Nov 28;77(12):3248-3255.
- [2]. H Takagi, et al. P031 Therapeutic effect of OPS‑2071 in a murine model of Crohn’s disease and in in vitro anti‑inflammatory assays. Journal of Crohn's and Colitis, 2020, 14(Supplement_1):S147.
